A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT01178086 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 681
Last updated 2018-10-05
Summary
This observational study will assess the therapeutic efficiency, treatment schedules, handling procedures, and the safety profile of rituximab in routine care in participants with CLL.
Conditions
- Lymphocytic Leukemia, Chronic
Interventions
- DRUG
-
Rituximab IV
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-02-22
- Primary Completion
- 2015-06-30
- Completion
- 2015-06-30
Countries
- Germany
Study Locations
More Related Trials
-
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
NCT01784068 ·Status: COMPLETED ·Phase: PHASE2
-
Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression
NCT02863718 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia
NCT01558167 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
NCT00001586 ·Status: COMPLETED ·Phase: PHASE2
-
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
NCT02420938 ·Status: WITHDRAWN ·Phase: PHASE2
-
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
NCT03788291 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
NCT05944978 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
NCT02758665 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
NCT01056510 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
NCT01808326 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT00801060 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02200848 ·Status: TERMINATED ·Phase: PHASE1
-
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT01243190 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02117336 ·Status: SUSPENDED ·Phase: PHASE1
-
Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT00081887 ·Status: TERMINATED ·Phase: PHASE1
-
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
NCT00836043 ·Status: TERMINATED
-
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
NCT01556776 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
NCT03289182 ·Status: COMPLETED
-
A Study to Evaluate ICP-022 in Patients With CLL/ SLL
NCT03493217 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT01486797 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
NCT00267059 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
NCT00860457 ·Status: COMPLETED ·Phase: PHASE2
-
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00694590 ·Status: COMPLETED ·Phase: PHASE1
-
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00096044 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02968563 ·Status: COMPLETED ·Phase: PHASE2